Get the Stockscreener App
9.08
5.21%
0.45
Verastem Inc stock is traded at $9.08, with a volume of 4.82M.
It is up +5.21% in the last 24 hours and up +72.30% over the past month.
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.
See More
Previous Close:
$8.63
Open:
$8.63
24h Volume:
4.82M
Relative Volume:
1.91
Market Cap:
$558.83M
Revenue:
$3.64M
Net Income/Loss:
$-87.37M
P/E Ratio:
-2.2092
EPS:
-4.11
Net Cash Flow:
$-86.46M
1W Performance:
+10.46%
1M Performance:
+72.30%
6M Performance:
+59.86%
1Y Performance:
+278.33%
1-Day Range:
$8.55
$9.40
1-Week Range:
$7.55
$9.40
52-Week Range:
$2.34
$9.40
Verastem Inc Stock (VSTM) Company Profile
Name
Verastem Inc
Sector
Industry
Phone
(781) 292-4200
Address
117 KENDRICK STREET, NEEDHAM, MA
Compare VSTM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VSTM
Verastem Inc
|
9.08 | 490.52M | 3.64M | -87.37M | -86.46M | -4.11 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Verastem Inc Stock (VSTM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-10-25 | Initiated | Jefferies | Buy |
| Mar-24-25 | Reiterated | H.C. Wainwright | Buy |
| Dec-31-24 | Reiterated | BTIG Research | Buy |
| Sep-30-24 | Initiated | Guggenheim | Buy |
| Nov-21-23 | Resumed | BTIG Research | Buy |
| Sep-27-23 | Initiated | B. Riley Securities | Buy |
| Jun-15-23 | Upgrade | Mizuho | Neutral → Buy |
| Sep-07-22 | Resumed | Alliance Global Partners | Buy |
| Apr-29-22 | Resumed | Cantor Fitzgerald | Overweight |
| Apr-14-22 | Initiated | RBC Capital Mkts | Outperform |
| Mar-09-22 | Initiated | Truist | Buy |
| Jul-01-21 | Initiated | Alliance Global Partners | Buy |
| May-24-21 | Upgrade | BTIG Research | Neutral → Buy |
| Jun-20-19 | Downgrade | BTIG Research | Buy → Neutral |
| May-10-19 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jul-13-18 | Initiated | BTIG Research | Buy |
| May-02-18 | Initiated | Seaport Global Securities | Buy |
| Mar-08-18 | Initiated | B. Riley FBR, Inc. | Buy |
| Sep-07-17 | Reiterated | H.C. Wainwright | Buy |
| Apr-13-17 | Initiated | Oppenheimer | Outperform |
| Mar-24-17 | Reiterated | H.C. Wainwright | Buy |
| Sep-29-15 | Downgrade | Cantor Fitzgerald | Buy → Hold |
| Sep-29-15 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Sep-29-15 | Downgrade | Jefferies | Buy → Hold |
| Sep-29-15 | Downgrade | Raymond James | Strong Buy → Outperform |
| Sep-28-15 | Downgrade | Mizuho | Buy → Neutral |
| Sep-28-15 | Downgrade | ROTH Capital | Buy → Neutral |
| Sep-09-15 | Initiated | Raymond James | Strong Buy |
| May-12-15 | Reiterated | UBS | Buy |
| Apr-08-15 | Initiated | H.C. Wainwright | Buy |
| Jan-23-15 | Reiterated | ROTH Capital | Buy |
| Jul-08-14 | Resumed | Oppenheimer | Perform |
| Feb-11-14 | Initiated | Mizuho | Buy |
View All
Verastem Inc Stock (VSTM) Latest News
Verastem Advances with Phase 3 Trial Progress and Product Launch Boosting Prospects - MSN
Mizuho lowers Verastem stock price target to $14 on dilution from financing By Investing.com - Investing.com South Africa
Verastem Inc. Earnings Call: Positive Outlook with Key Achievements - MSN
Mizuho lowers Verastem stock price target to $14 on dilution from financing - Investing.com
Why Verastem Inc. stock attracts strong analyst attentionEarnings Recap Report & High Return Stock Watch Alerts - thegnnews.com
Verastem’s VS-7375 shows efficacy in lung cancer - MSN
Verastem Oncology's Breakthrough in KRAS-Driven Cancers and the High-Potential Launch of AVMAPKI FAKZYNJA CO-PACK - AInvest
Verastem price target lowered to $14 from $16 at Mizuho - MSN
Verastem Receives Buy Rating from Mizuho Securities with $14 Price Target - AInvest
Mizuho Securities Cuts Price Target on Verastem to $14 From $16, Maintains Outperform Rating - MarketScreener
Breakout Traders Target Verastem Inc. on Recovery SetupWeekly Market Outlook & Precise Swing Trade Entry Alerts - metal.it
Verastem shares rise 8.48% premarket after partner's trial data for GFH375 in lung cancer. - AInvest
Verastem stock rises as BTIG reiterates Buy rating on improved cancer drug data By Investing.com - Investing.com South Africa
Verastem stock rises as BTIG reiterates Buy rating on improved cancer drug data - Investing.com Australia
Verastem Soars 16.58% on Positive NSCLC Trial Data - AInvest
Verastem Oncology Announces Late-Breaking Abstract from Partner GenFleet Therapeutics’ Study in China of GFH375 (VS-7375) in Advanced Non-Small Cell Lung Cancer at IASLC 2025 World Conference on Lung Cancer - BioSpace
Verastem Unveils Promising VS-7375 Study Results - TipRanks
Verastem stock soars after KRAS inhibitor shows strong lung cancer results By Investing.com - Investing.com South Africa
Verastem stock soars after KRAS inhibitor shows strong lung cancer results - Investing.com India
Verastem Oncology Announces Late-Breaking Abstract from Partner - GuruFocus
Verastem Oncology Announces Positive Efficacy Data for Partner GenFleet Therapeutics' KRAS G12D Inhibitor VS-7375 in Advanced Non-Small Cell Lung Cancer. - AInvest
New Lung Cancer Drug Achieves Breakthrough 69% Response Rate in Advanced NSCLC Patients - Stock Titan
Verastem, Inc. (NASDAQ:VSTM) Q2 2025 Earnings Call Transcript - Insider Monkey
Can Verastem Inc. stock double in the next yearReturn-Focused Stock Plans - thegnnews.com
Will Verastem’s Stock Keep Rising? - StocksToTrade
Verastem (VSTM.O) Surges 19.9% on KDJ Golden Cross and Mysterious Order Flow - AInvest
Verastem Second Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Verastem Seeks to Raise $300M through Mixed Securities Shelf - AInvest
Verastem's New Ovarian Cancer Drug Sees Strong Sales, Analysts Predict Significant Upside - AInvest
Verastem (VSTM.O) Surges 19.9%: What’s Behind the Sharp Intraday Move? - AInvest
Verastem's Q2 Earnings Exceed Expectations on Strong Ovarian Cancer Drug Sales - AInvest
Using Python tools to backtest Verastem Inc. strategiesAI Trend Detection for Entry Timing - Newser
What makes Verastem Inc. stock price move sharplyMassive ROI Stock Selections - thegnnews.com
Verastem's (VSTM) Breakthrough in KRAS-Driven Cancers and Commercialization Momentum - AInvest
Transcript : Verastem, Inc., Q2 2025 Earnings Call, Aug 07, 2025 - MarketScreener
Verastem stock climbs on Q2 beat (VSTM:NASDAQ) - Seeking Alpha
Verastem’s Promising Phase 3 Study in Ovarian Cancer: A Potential Game-Changer? - TipRanks
RBC Raises Price Target on Verastem to $13 From $12, Keeps Outperform, Speculative Risk - MarketScreener
Verastem Inc files for mixed shelf offering of up to $300 millionSEC filing - MarketScreener
Earnings call transcript: Verastem Q2 2025 sees revenue growth and FDA approval - Investing.com
Verastem’s Promising Market Expansion and Financial Health Drive Buy Rating - TipRanks
Verastem: Q2 Earnings Snapshot - Connecticut Post
Verastem Q2 2025 Earnings Call Transcript - MarketBeat
Verastem Inc (VSTM) Q2 2025 Earnings Call Highlights: FDA Approval and Strong Launch Drive ... By GuruFocus - Investing.com Canada
Verastem Oncology’s Q2 2025 Financial and Business Highlights - TipRanks
Verastem Inc (VSTM) Q2 2025 Earnings Call Highlights: FDA Approval and Strong Launch Drive Positive Momentum - GuruFocus
Verastem Oncology Reports Second Quarter 2025 Financial Results and Highlights Recent Business Updates - BioSpace
Verastem 2025 Q2 Earnings Deepened Losses Amid Product Launch - AInvest
Verastem Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Custom strategy builders for tracking Verastem Inc.Free Short Term Buy List With Stop Protection - Newser
Verastem Oncology Gambles On Cancer Drug Launch Despite Deepening Losses - Finimize
Verastem Inc Stock (VSTM) Financials Data
Revenue
Net Income
Cash Flow
EPS
Verastem Inc Stock (VSTM) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Paterson Dan | President and CEO |
Jun 20 '25 |
Sale |
5.13 |
17,808 |
91,355 |
443,839 |
| Calkins Daniel | Chief Financial Officer |
Jun 20 '25 |
Sale |
5.13 |
4,110 |
21,084 |
109,945 |
| Calkins Daniel | Chief Financial Officer |
Jun 23 '25 |
Sale |
4.71 |
25 |
118 |
109,920 |
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):